X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (592) 592
humans (580) 580
infectious diseases (362) 362
hiv infections - drug therapy (342) 342
male (315) 315
adult (296) 296
female (288) 288
virology (280) 280
immunology (237) 237
hiv infections - virology (224) 224
hiv (197) 197
middle aged (197) 197
aids/hiv (175) 175
hiv-1 - drug effects (171) 171
pharmacology & pharmacy (153) 153
hiv-1 - genetics (149) 149
anti-hiv agents - therapeutic use (148) 148
viral load (145) 145
human immunodeficiency virus--hiv (140) 140
microbiology (133) 133
antiretroviral therapy (131) 131
hiv infection (116) 116
cd4 lymphocyte count (114) 114
hiv infections - immunology (114) 114
infection (112) 112
hiv-1 (110) 110
aids (97) 97
treatment outcome (96) 96
antiretroviral drugs (95) 95
anti-hiv agents - pharmacology (94) 94
drug therapy (93) 93
human-immunodeficiency-virus (91) 91
mutation (91) 91
drug therapy, combination (86) 86
hiv infections - complications (85) 85
protease inhibitors (84) 84
antiretroviral therapy, highly active (83) 83
antiviral agents (83) 83
anti-hiv agents - administration & dosage (81) 81
genotype (80) 80
hiv-1 - physiology (80) 80
research (79) 79
therapy (72) 72
active antiretroviral therapy (71) 71
rna, viral - blood (71) 71
health aspects (70) 70
immunodeficiency-virus type-1 (68) 68
human immunodeficiency virus (63) 63
hiv protease inhibitors - therapeutic use (60) 60
risk factors (60) 60
drug resistance, viral (57) 57
drug resistance (56) 56
hiv-1 - isolation & purification (56) 56
replication (55) 55
highly active antiretroviral therapy (54) 54
hiv-1-infected patients (53) 53
time factors (53) 53
anti-hiv agents - adverse effects (51) 51
care and treatment (50) 50
efficacy (50) 50
prospective studies (50) 50
drug resistance, viral - genetics (49) 49
prevalence (49) 49
ritonavir - therapeutic use (48) 48
treatment failure (48) 48
abridged index medicus (47) 47
hiv-infected patients (47) 47
resistance (47) 47
viruses (47) 47
analysis (44) 44
cohort studies (44) 44
hiv-1 - immunology (44) 44
reverse transcriptase inhibitors - therapeutic use (44) 44
tenofovir (44) 44
infections (43) 43
retrospective studies (43) 43
virus diseases (43) 43
aged (42) 42
clinical trials (42) 42
disease progression (42) 42
acquired immune deficiency syndrome--aids (41) 41
drug administration schedule (41) 41
medicine (41) 41
molecular sequence data (41) 41
cell line (40) 40
cross-sectional studies (40) 40
patients (38) 38
phenotype (38) 38
rna (38) 38
hiv infections - blood (37) 37
hiv patients (37) 37
antiretrovirals (36) 36
safety (36) 36
cd4 antigen (35) 35
research article (35) 35
young adult (35) 35
antiretroviral therapy, highly active - methods (34) 34
combination therapy (34) 34
amino acid sequence (33) 33
hiv infections - epidemiology (33) 33
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2222 - 2231
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9581, pp. 39 - 48
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 5, pp. 363 - 371
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9568, pp. 1169 - 1178
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 587 - 596
Journal Article
JAMA, ISSN 0098-7484, 07/2016, Volume 316, Issue 2, pp. 171 - 181
Journal Article
The Lancet, ISSN 0140-6736, 09/2017, Volume 390, Issue 10101, pp. 1499 - 1510
Journal Article